DaVita Inc. (NYSE:DVA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on DaVita, with four buy ratings and three holds. The average 12-month price target is approximately $233.43, though recent targets range from $215 to $270.
• DaVita exceeded quarterly expectations, reporting $4.02 in EPS versus the $3.88 consensus and $3.55 billion in revenue, up 5.2% year over year. Management provided fiscal 2026 EPS guidance of $14.10 to $15.20.
• Shares recently traded at $183.26, while institutional investors own approximately 90.12% of the company.

DaVita Inc. (NYSE:DVA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $233.4286.

DVA has been the subject of several research analyst reports. Weiss Ratings upgraded shares of DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 5th. Truist Financial lowered their price objective on DaVita from $250.00 to $215.00 and set a "hold" rating on the stock in a report on Friday, August 7th. Oppenheimer set a $220.00 target price on DaVita in a report on Friday, August 7th. TD Cowen upgraded DaVita from a "hold" rating to a "buy" rating and raised their target price for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Finally, UBS Group boosted their price target on DaVita from $235.00 to $270.00 and gave the stock a "buy" rating in a research report on Friday, July 10th.

DaVita Trading Up 0.1%

Shares of DVA traded up $0.17 during mid-day trading on Friday, hitting $183.26. The company's stock had a trading volume of 97,851 shares, compared to its average volume of 917,797. The firm has a market capitalization of $11.69 billion, a price-to-earnings ratio of 14.99, a PEG ratio of 0.50 and a beta of 0.83. The company's 50-day moving average is $200.58 and its 200-day moving average is $186.72. DaVita has a 52-week low of $101.00 and a 52-week high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.50 billion. During the same period last year, the business posted $2.95 earnings per share. The firm's revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts predict that DaVita will post 14.57 earnings per share for the current fiscal year.

Institutional Trading of DaVita

Hedge funds and other institutional investors have recently made changes to their positions in the company. Root Financial Partners LLC lifted its stake in DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company's stock worth $29,000 after purchasing an additional 105 shares during the last quarter. Sankala Group LLC acquired a new position in DaVita in the fourth quarter worth $39,000. Fideuram Asset Management Ireland dac bought a new stake in DaVita during the fourth quarter valued at $49,000. Western Wealth Management LLC acquired a new stake in shares of DaVita during the first quarter worth $60,000. Finally, Canada Post Corp Registered Pension Plan grew its position in shares of DaVita by 51.6% during the 4th quarter. Canada Post Corp Registered Pension Plan now owns 558 shares of the company's stock valued at $63,000 after buying an additional 190 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Company Profile

DaVita Inc NYSE: DVA is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.